3B Blackbio Dx Limited Q3 FY26 results deck summary

Results deck of 6 Feb 2026, summarised by AI from the filing.

Q3 FY26 consolidated revenue ₹5,034.73 cr including CORIS ₹2,400.70 cr; MDx FY26 growth guided 10-15%.

Key takeaways

1. Q3 revenue Consolidated revenue ₹5,034.73 cr (Q3 FY25: ₹2,539.25 cr), including CORIS sales of ₹2,400.70 cr.
2. Coris acquisition Coris consolidated from 29 August; Q4 FY25 profit EUR 691K one-time due to HAT order.
3. Growth driver Export growth of 15-20% driven by quality, wide product range, fast delivery and tech support.
4. Risk Chinese competition causing de-growth in Coris Infectious segment and pressure on margins.

Original filing on BSE

3B Blackbio Dx Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (13 Aug 2026)
• Q4 FY26: Earnings call (1 Jun 2026), Results deck (29 May 2026)
• Q3 FY26: Earnings call (21 Feb 2026), Results deck (6 Feb 2026)
• Q2 FY26: Results deck (13 Nov 2025)
• Q1 FY26: Earnings call (19 Aug 2025)
• Q4 FY25: Results deck (28 May 2025)
• Other events: Strategy deck (14 Aug 2025)